MentionFox
Home › Stakes › Seaport Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

Seaport Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of Seaport Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more6
Filings6
Latest filing2026-08-14

Seaport Therapeutics, Inc. has 6 Schedule 13D or 13G filings on record since 2026-05-06. 6 holders' latest filing reports 5% or more of voting common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
PureTech Health plc31.2%16,685,013SCHEDULE 13G, 2026-08-142026-06-30
ARCH Venture Fund XII, L.P.11.9%6,294,951SCHEDULE 13D, 2026-05-062026-05-04
General Atlantic, L.P.11.5%6,101,582SCHEDULE 13D, 2026-05-112026-05-04
Zohar Daphne9.1%5,225,497SCHEDULE 13G, 2026-08-052026-06-30
Paul Steven M6.3%3,516,718SCHEDULE 13G, 2026-08-052026-06-30
The Goldman Sachs Group, Inc.5.5%2,791,814SCHEDULE 13G, 2026-05-112026-05-06

Purpose of Transaction (Item 4)

ARCH Venture Fund XII, L.P.

AVF XII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-05-06

General Atlantic, L.P.

The Reporting Persons acquired the common stock reported herein for investment purposes. Consistent with such purposes, the Reporting Persons may engage in communications with, without limitation, one or more shareholders of the Company, management of the Company, one or more members of the board of directors of the Company, and may make suggestions concerning the Company's operations, prospects, business and financial strategies, strategic transactions, assets and liabilities, business and financing alternatives, the composition of the board of directors of the Company and such other matters as the Reporting Persons may deem relevant to their investment in the common stock. The Reporting Persons expect that they will, from time to time, review their investment position in the common stock or the Company and may, depending on the Company's performance and other market conditions, increase or decrease their investment position in the common stock. The Reporting Persons may, from time to time, make additional purchases of common stock either in the open market or in privately-negotiated transactions, depending upon the Reporting Persons' evaluation of the Company's business, prospects and financial condition, the market for the common stock, other opportunities available to the Reporting Persons, general economic conditions, stock market conditions and other factors. Depending upon the factors noted above, the Reporting Persons may also decide to hold or dispose of all or …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-11; the filing has the rest

Timeline

FiledHolderPercentFiling
2026-05-06ARCH Venture Fund XII, L.P.11.9%SCHEDULE 13D
2026-05-11The Goldman Sachs Group, Inc.5.5%SCHEDULE 13G
2026-05-11General Atlantic, L.P.11.5%SCHEDULE 13D
2026-08-05Paul Steven M6.3%SCHEDULE 13G
2026-08-05Zohar Daphne9.1%SCHEDULE 13G
2026-08-14PureTech Health plc31.2%SCHEDULE 13G

Tools for this story

Each opens in a new tab, filled in for Seaport Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/seaport-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Seaport Therapeutics, Inc. 5%+ holders: 6 at 5% or more, largest PureTech Health plc 31.2%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/seaport-therapeutics